Abraham L Brass

US Patent:

20120331576, Dec 27, 2012

Filed:

Dec 10, 2010

Appl. No.:

13/511980

Inventors:

Abraham Brass - Newton MA, US
Stephen Elledge - Brookline MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - Boston MA
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

C12N 5/10
C12Q 1/68
C12Q 1/70
A01K 67/027
A61P 31/04
A61K 9/127
A61K 38/17
C12N 7/00
A61P 31/12

US Classification:

800 17, 435366, 435325, 435349, 4352351, 435 613, 435 5, 514 37, 514 24, 424450, 800 13, 800 19

Abstract:

The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein

US Patent:

20100273859, Oct 28, 2010

Filed:

Dec 15, 2008

Appl. No.:

12/747041

Inventors:

Stephen Elledge - Brookline MA, US
Judy Lieberman - Brookline MA, US
Abraham L. Brass - Newton MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
IMMUNE DISEASE INSTITUTE, INC. - Boston MA
THE GENERAL HOSPITAL CORPORATION - Boston MA

International Classification:

A61K 31/713
C07H 21/02
A61P 31/18

US Classification:

514 44 A, 536 245

Abstract:

Disclosed herein are methods for treating and/or preventing HIV infection in a cell. The methods involve downmodulating one or more of the HIV-dependency factors (HDFs) disclosed herein to thereby treat and/or prevent HIV infection in the cell. Downmodulating the HDFs can be by contacting the cell with an agent that downmodulates the HDF. Also disclosed herein are methods for treating and/or preventing HIV infection in a subject comprising downmodulating one or more of the HIV-dependency factors (HDFs), disclosed herein, to thereby treat and/or prevent HIV infection in the subject. The method may further comprise selecting a subject diagnosed with or at risk for HIV infection, prior to downmodulating. Downmodulating the HDFs may comprise administering an agent that downmodulates the HDF to the subject such that the agent contacts HIV host cells of the subject. The agent may inhibit HDF gene expression, protein synthesis, HDF function or HDF activity, or combinations thereof.

US Patent:

20230034732, Feb 2, 2023

Filed:

Sep 20, 2022

Appl. No.:

17/933709

Inventors:

- Boston MA, US
Xiaofei E - Westborough MA, US
Abraham L. Brass - Newton MA, US

International Classification:

A61K 38/17
A61K 31/52
C07K 16/28
C12N 15/113

Abstract:

Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.

US Patent:

20200376077, Dec 3, 2020

Filed:

Apr 13, 2018

Appl. No.:

16/604735

Inventors:

- Boston MA, US
Xiaofei E - Westborough MA, US
Abraham L. Brass - Newton MA, US

International Classification:

A61K 38/17
C07K 16/28
C12N 15/113
A61K 31/52

Abstract:

Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.

US Patent:

20190216835, Jul 18, 2019

Filed:

Jun 6, 2017

Appl. No.:

16/306842

Inventors:

- Boston MA, US
Abraham L. Brass - Newton MA, US

International Classification:

A61K 31/7048
A61K 31/7056
A61K 31/35
A61P 31/14

Abstract:

Methods for treating or reducing the risk of developing Zika virus infection in a subject, comprising administering an effective amount of lanatoside C, ribavirin and/or ivermectin to the subject.